Abstract
The amyloid-β peptide (Aβ) is the major protein component of the characteristic cerebral plaques of Alzheimers disease (AD), and a large body of evidence supports a pathogenic role for this peptide. Thus, the proteases β- and γ-secretase that are responsible for carving Ab out of its precursor protein are considered prime targets for therapeutic design. β-Secretase is a membrane-anchored aspartyl protease of the pepsin family, while γ-secretase is much more complex. γ-Secretase requires presenilin, a multipass membrane protein that is the site of dozens of missense mutations that alter Ab formation and cause hereditary AD. Two conserved aspartates in presenilin are required for γ-secretase activity, and aspartyl protease transition-state analogue inhibitors of γ-secretase bind directly to presenilins, strong evidence that presenilin is the catalytic component of a novel membrane aspartyl protease. γ-Secretase appears to be a multi-component complex of integral membrane proteins, and so far presenilin and a single-pass membrane protein called nicastrin have been identified as members of this complex. A closely similar or identical protease activity is essential for a signaling pathway critical for embryogenesis and hematopoiesis, raising concerns about γ-secretase as a target. The development of potent and selective inhibitors with good pharmacokinetic properties may soon address these concerns.
Keywords: presenilin
Current Topics in Medicinal Chemistry
Title: γ-Secretase as a Target for Alzheimers Disease
Volume: 2 Issue: 4
Author(s): Michael S. Wolf
Affiliation:
Keywords: presenilin
Abstract: The amyloid-β peptide (Aβ) is the major protein component of the characteristic cerebral plaques of Alzheimers disease (AD), and a large body of evidence supports a pathogenic role for this peptide. Thus, the proteases β- and γ-secretase that are responsible for carving Ab out of its precursor protein are considered prime targets for therapeutic design. β-Secretase is a membrane-anchored aspartyl protease of the pepsin family, while γ-secretase is much more complex. γ-Secretase requires presenilin, a multipass membrane protein that is the site of dozens of missense mutations that alter Ab formation and cause hereditary AD. Two conserved aspartates in presenilin are required for γ-secretase activity, and aspartyl protease transition-state analogue inhibitors of γ-secretase bind directly to presenilins, strong evidence that presenilin is the catalytic component of a novel membrane aspartyl protease. γ-Secretase appears to be a multi-component complex of integral membrane proteins, and so far presenilin and a single-pass membrane protein called nicastrin have been identified as members of this complex. A closely similar or identical protease activity is essential for a signaling pathway critical for embryogenesis and hematopoiesis, raising concerns about γ-secretase as a target. The development of potent and selective inhibitors with good pharmacokinetic properties may soon address these concerns.
Export Options
About this article
Cite this article as:
Wolf S. Michael, γ-Secretase as a Target for Alzheimers Disease, Current Topics in Medicinal Chemistry 2002; 2 (4) . https://dx.doi.org/10.2174/1568026024607535
DOI https://dx.doi.org/10.2174/1568026024607535 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Mechanisms Mediating Nociceptin/Orphanin FQ Receptor Signaling, Desensitization and Internalization
Current Molecular Pharmacology The Sphingolipid Rheostat: A Potential Target for Improving Pancreatic Islet Survival and Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake
Current Alzheimer Research Fitness or Fatness: The Debate Continues for AMP-Activated Protein Kinase in Heart Function
Current Cardiology Reviews Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Current Neuropharmacology Neurodevelopment in Schizophrenia: The Role of the Wnt Pathways
Current Neuropharmacology COMMENTARY: Magnetic Resonance Techniques Applied to Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Acetylcholinesterase Inhibitors as Pretreatment Before Acute Exposure to Organophosphates: Assessment Using Methyl-Paraoxon
CNS & Neurological Disorders - Drug Targets MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design A Resurrection of 7-MEOTA: A Comparison with Tacrine
Current Alzheimer Research Neurobehavioral and Cognitive Changes Induced by Hypoxia in Healthy Volunteers
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms of Thiamine Utilization.
Current Molecular Medicine Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Yoga may Prevent Cytokine Storm in COVID-19
Coronaviruses Discovery of New Potential Antimalarial Compounds Using Virtual Screening of ZINC Database
Combinatorial Chemistry & High Throughput Screening Edging Toward Personalized Medicine
Current Pharmacogenomics Anti-Hormonal Therapies for Premenopausal Patients – What did we Learn from the TEXT/SOFT Trials?
Reviews on Recent Clinical Trials